Kardigan Turned Deal Leftovers Into a $400M IPO

Kardigan has completed a $400 million IPO, according to a report by BioPharma Dive.

The company was built from assets that a larger deal partner chose not to keep — what BioPharma Dive calls "deal leftovers." Rather than letting those programs lapse, Kardigan's founders spun them into an independent biotech and carried it to a public listing worth $400 million.

The BioPharma Dive headline framing — "How Kardigan spun deal leftovers into a $400M IPO" — points to a familiar pattern in the biopharma sector: when large pharmaceutical companies merge, restructure or reprioritize, experimental programs that no longer fit the strategy are often divested or shelved. Smaller teams frequently acquire rights to those compounds at modest cost and advance them independently. A $400 million IPO demonstrates that public-market investors were willing to fund that strategy.

What the headline establishes

• Kardigan raised $400 million through an initial public offering.
• The company's foundation traces back to assets discarded or excluded from a prior deal.
• BioPharma Dive reported the story.

The syndicated feed available to Business Bearings at publication time contained only the article headline and the $400 million IPO figure. Additional deal terms — the pricing date, share count, offering price, lead investors, pipeline assets and the identity of the divesting partner — appear in the full BioPharma Dive report, which subscribers can consult directly.

Why it matters

A $400 million debut is a substantial sum for a company whose origin lies in cast-off assets. It signals that underwriting banks and institutional investors see value in programs that original owners chose not to fund, and it may encourage more spin-out formations from corporate portfolios in the current financing window.

Business Bearings will update this story as the full offering details become available.